Celator Pharmaceuticals today announced that the European Commission has granted orphan drug status to CPX-351, the company’s proprietary “liposomal combination of cytarabine and daunorubicin,” for the treatment of acute myeloid leukemia .
Continue reading here:
Celator® Pharmaceuticals Receives EMA Orphan Drug Status for CPX-351 in Acute Myeloid Leukemia